Phase II trial of topotecan for the treatment of mesothelioma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 610-613

  Maksymiuk, Andrew W ^a   Marschke Jr , Robert F ^b   Tazelaar, Henry D ^c   Grill, Joe ^c   Nair, Suresh ^d   Marks, Randolph S ^g   Brooks, B Jay ^g   Mailliard, James A ^e   Burton, G Mark ^g   Jett, James R ^c,f  

^a Saskatoon Cancer Center   (Canada)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e CREIGHTON UNIVERSITY   (United States)

^f North Central Cancer Treatment Group Rochester   (United States)

^g NONE

Author keywords

Mesothelioma; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; FEVER; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 0031793811     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00017     Document Type: Article

References (16)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1992. CA Cancer J Clin 1992;42:19-38.
2. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol 1992;19:64-71.
3. Ruffie, P. Pleural mesothelioma. Curr Opin Oncol 1992;4:334-41.
4. Adams VI, Krishnan UK, Muhm JR, Jett JR, Ilstrup DM, Bernats PE. Diffuse malignant mesothelioma of pleura. Cancer 1986;58:1540-51.
5. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
6. Antman KH, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over 2 decades 1965-1985. J Clin Oncol 1988;6:147-53.
7. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991;28:319-30.
8. Johnson FK, Hertzberg RP, Kingsburg WD, et al. Preclinical profile of SK&F 104864, a water soluble analog of camptothecin. Proceedings of the Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989;301.
9. Kingsburg WD, Boehm JC, Jakas DR, et al. Synthesis of water soluble (aminoalkyl) camptothecin analogs: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1991;34:98-107.
10. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I target chemotherapy of human colon cancer xenografts. Science 1989;246:1048.
11. Rowinsky EK, Grochow LB, Hendricks CT, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
12. Jett JR, Su JQ, Krook JE, Goldberg RM, Kugler JW. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol 1994;12:2677-81.
13. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987;43:81-93.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958;53:457-81.
15. Vogelzang NJ, Weissman LB, Herndon II JE, et al. Trimetrexate in malignant mesothelioma: a cancer and leukemia group B phase II study. J Clin Oncol 1994;12:1436-42.
16. Curiel DT, Pilewski JM, Albelda SM. Gene therapy approaches for inherited and acquired lung diseases. American Review of Respiratory Cell and Molecular Biology 1996;14:1-18.